This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


Concluding Discussion: Pharmacoeconomic Factors Related to the Treatment of Schizophrenia


Published: March 1, 1999

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Dr. H. Meltzer: Readers of this Supplement should find answers to questions such as: How should various stakeholders evaluate cost effectiveness? Is cost-utility analysis an accepted form of research? Why should managed care companies or government agencies be interested in pharmacoeconomic analysis?’ ‹

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 60

Quick Links: